ABCL Q3 2023 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena

ABCLAbCellera Biologics Inc.

$1B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M-93.5% YoY

Gross Profit

$7M100.0% margin

Operating Income

-$55M-831.8% margin

Net Income

-$29M-433.6% margin

EPS (Diluted)

$-0.10

QoQ Revenue Growth

-34.4%

Cash Flow

Operating Cash Flow

-$106,000

Free Cash Flow

-$20M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$329M

Stockholders' Equity

$1.2B

Cash & Equivalents

$172M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$101M	-93.5%
Gross Profit	$7M	$86M	-92.4%
Operating Income	-$55M	$38M	-245.5%
Net Income	-$29M	$27M	-207.5%

Revenue Segments

Research Fees

$6M97%

License

$186,0003%